β2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model

American Journal of Respiratory Cell and Molecular Biology

Volumn 48, Issue 2, 2013, Pages 220-229

  Thanawala, Vaidehi J ^a   Forkuo, Gloria S ^a   Al Sawalha, Nour ^a   Azzegagh, Zoulikha ^b   Nguyen, Long P ^b   Eriksen, Jason L ^a   Tuvim, Michael J ^b   Lowder, Thomas W ^a   Dickey, Burton F ^b   Knoll, Brian J ^a   Walker, Julia K L ^c   Bond, Richard A ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

2 adrenoceptor agonists; Asthma; Epinephrine; Formoterol; Murine model

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; MUCIN; OVALBUMIN; PHENYLETHANOLAMINE N METHYLTRANSFERASE; RESERPINE;

AIRWAY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; ATTENUATION; CLINICAL FEATURE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL REGULATION; INFLAMMATORY CELL; LUNG LAVAGE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN SYNTHESIS; RESPIRATORY TRACT ALLERGY; SENSITIZATION; SYMPATHECTOMY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; ASTHMA; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; EPINEPHRINE; ETHANOLAMINES; MICE; MICE, KNOCKOUT; MUCINS; PHENOTYPE;

EID: 84873369705     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0364OC     Document Type: Article

References (42)

1. American Lung Association. American Lung Association. Trends in asthma morbidity and mortality. Washington, DC: American Lung Association Epidemiology & Statistics Unit Research and Program Services; 2007.
2. Rau JL. Inhaled adrenergic bronchodilators: historical development and clinical application. Respir Care 2000;45:854-863.
3. Tattersfield AE. Current issues with beta2-adrenoceptor agonists: historical background. Clin Rev Allergy Immunol 2006;31:107-118.
4. Aldington S, Beasley R. Asthma exacerbation: 5. Assesment and management of severe asthma in adults in hospital. Thorax 2007;62:447-458.
5. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, Lazarus SC, Lemanske RF, Martin RJ, Peters SP, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996;335:841-847.
6. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995;96:44-49.
7. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med 2003;2:287-297.
8. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-912.
9. Shore SA, Drazen JM. Beta-agonists and asthma: too much of a good thing? J Clin Invest 2003;112:495-497.
10. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists: is there cause for concern? Drug Saf 1997;16:295-308.
11. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
12. Callaerts-Vegh Z, Evans KL, Dudekula N, Cuba D, Knoll BJ, Callaerts PF, Giles H, Shardonofsky FR, Bond RA. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 2004;101: 4948-4953.
13. Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, Parra S, Bond RA. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther 2008;21:115-124.
14. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, et al. Chronic exposure to β-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008;38:256-262.
15. 2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci USA 2009;106:2435-2440.
16. Piccotti L, Dickey BF, Evans CM. Assessment of intracellular mucin content in vivo. Methods Mol Biol 2012;842:279-295.
17. Evans KL, Bond RA, Corry DB, Shardonofsky FR. Frequency dependence of respiratory system mechanics during induced constriction in a murine model of asthma. J Appl Physiol 2003;94:245-252.
18. Patki G, Che Y, Lau YS. Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease. Front Aging Neurosci 2009;1:3.
19. Rosner B. Fundamentals of biostatistics. Boston: Brooks/Cole, Cengage Learning; 2011.
20. Guide to receptors and channels (GRAC), 4th ed. Br J Pharmacol 2009; 158:S1-S254.
21. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967;214:597-598.
22. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 2011.
23. Evans CM, Williams OW, Tuvim MJ, Nigam R, Mixides GP, Blackburn MR, DeMayo FJ, Burns AR, Smith C, Reynolds SD, et al. Mucin is produced by Clara cells in the proximal airways of antigen-challenged mice. Am J Respir Cell Mol Biol 2004;31:382-394.
24. Chen G, Korfhagen TR, Xu Y, Kitzmiller J, Wert SE, Maeda Y, Gregorieff A, Clevers H, Whitsett JA. SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. J Clin Invest 2009;119:2914-2924.
25. Moore RH, Millman EE, Godines V, Hanania NA, Tran TM, Peng H, Dickey BF, Knoll BJ, Clark RB. Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. Am J Respir Cell Mol Biol 2007;36:254-261.
26. Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2012;4: CD006923.
27. Harcourt LJ, Schertzer JD, Ryall JG, Lynch GS. Low dose formoterol administration improves muscle function in dystrophic MDX mice without increasing fatigue. Neuromuscul Disord 2007;17:47-55.
28. Pearen MA, Myers SA, Raichur S, Ryall JG, Lynch GS, Muscat GE. The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 2008;149:2853-2865.
29. Leger B, Koopman R, Walrand S, Gehrig SM, Murphy KT, Lynch GS. Chronic formoterol administration reduces cardiac mitochondrial protein synthesis and oxidative capacity in mice. Int J Cardiol 2011; 146:270-272.
30. Koopman R, Gehrig SM, Leger B, Trieu J, Walrand S, Murphy KT, Lynch GS. Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic {beta}-adrenoceptor stimulation in mice. J Physiol 2010;588:4811-4823.
31. Ebert SN, Rong Q, Boe S, Thompson RP, Grinberg A, Pfeifer K. Targeted insertion of the cre-recombinase gene at the phenylethanolamine n-methyltransferase locus: a new model for studying the developmental distribution of adrenergic cells. Dev Dyn 2004;231:849-858.
32. Sun P, Bao X, Elayan H, Milic M, Liu F, Ziegler MG. Epinephrine regulation of hemodynamics in catecholamine knockouts and the pithed mouse. Ann N Y Acad Sci 2008;1148:325-330.
33. Sharara-Chami RI, Joachim M, Mulcahey M, Ebert S, Majzoub JA. Effect of epinephrine deficiency on cold tolerance and on brown adipose tissue. Mol Cell Endocrinol 2010;328:34-39.
34. Ziegler MG, Milic M, Sun P, Tang CM, Elayan H, Bao X, Cheung WW, O'Connor DT. Endogenous epinephrine protects against obesity induced insulin resistance. Auton Neurosci 2011;162:32-34.
35. Bond RA. Is paradoxical pharmacology a strategy worth pursuing? Trends Pharmacol Sci 2001;22:273-276.
36. Bond RA. Can intellectualism stifle scientific discovery? Nat Rev Drug Discov 2002;1:825-829.
37. Hanania NA, Mannava B, Franklin AE, Lipworth BJ, Williamson PA, Garner WJ, Dickey BF, Bond RA. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J 2010;36: 963-965.
38. Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008;21:134-141.
39. Parra S, Bond RA. Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? Curr Opin Pharmacol 2007;7: 146-150.
40. Walker JK, Penn RB, Hanania NA, Dickey BF, Bond RA. New per-spectives regarding beta(2)-adrenoceptor ligands in the treatment of asthma. Br J Pharmacol 2011;163:18-28.
41. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, Yates DM, Lucas MK, Herbison GP. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-1396.
42. Walker JK, Fong AM, Lawson BL, Savov JD, Patel DD, Schwartz DA, Lefkowitz RJ. Beta-arrestin-2 regulates the development of allergic asthma. J Clin Invest 2003;112:566-574.